Get Live Data

Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globally
Rainbow Rare Earths Phalaborwa project shaping up to be one of the lowest cost producers globallyView Video

Latest Share Chat

  2. Share Prices
  3. Genedrive Share Price
  4. Genedrive Share Regulatory News
  5. Change of Adviser

Pin to quick picksGenedrive Regulatory News (GDR)

Genedrive Information

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.675
Bid: 1.65
Ask: 1.70
Change: 0.00 (0.00%)
Spread: 0.05 (3.03%)
Open: 1.675
High: 1.725
Low: 1.625
Prev. Close: 1.675
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Change of Adviser

9 Mar 2010 07:00

RNS Number : 2311I
Epistem Holdings plc
09 March 2010
 

FINAL DRAFT

9 March 2010

 

Epistem Holdings Plc ("Epistem")

 

Change of Nominated Adviser and Broker

 

Epistem (LSE: EHP), the rapidly growing UK biotechnology company with adult epithelial stem cell expertise in oncology, gastrointestinal and dermatological diseases today announces the appointment of KBC Peel Hunt Ltd as its nominated adviser and broker with immediate effect.

 

For further information, please contact:

Epistem Plc

Matthew Walls Chief Executive Officer 07887 501998

John Rylands Finance Director 0161 606 7244

 

KBC Peel Hunt Ltd

James Steel Qualified Executive 020 7418 8900

Vijay Barathan 020 7418 8900

 

De Facto Communications

Mike Wort / Anna Dunphy 020 7861 3838

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPMMGGFZRRGGZM
5678910111213
Date   Source Headline
4th Mar 20203:33 pmRNSGrant of options
13th Feb 20209:53 amRNSHolding(s) in Company
11th Feb 20204:00 pmRNSDirector/PDMR Shareholding
6th Feb 20204:30 pmRNSHolding(s) in Company
5th Feb 20205:38 pmRNSDirector/PDMR Shareholding
5th Feb 20205:32 pmRNSDirector/PDMR Shareholding
5th Feb 20204:45 pmRNSHolding(s) in Company
5th Feb 20207:15 amEQSHardman & Co Research: genedrive plc (GDR): Western market progress but developing markets difficult
4th Feb 20204:25 pmRNSDirector/PDMR Shareholding
4th Feb 20202:06 pmRNSSecond Price Monitoring Extn
4th Feb 20202:00 pmRNSPrice Monitoring Extension
4th Feb 20207:00 amRNSHalf-year Report
15th Jan 20207:00 amRNSNotice of Results
11th Dec 20195:24 pmRNSHolding(s) in Company
11th Dec 201910:06 amRNSHolding(s) in Company
5th Dec 201911:30 amRNSAdditional Listing
3rd Dec 20197:00 amRNSAIHL assay kit demonstrates high clinical accuracy
27th Nov 20194:23 pmRNSResult of AGM
22nd Nov 20192:41 pmRNSDirector/PDMR Shareholding
21st Nov 201912:30 pmEQSHardman & Co Research: genedrive plc (GDR): Regulatory hurdle leaped: hearing loss assay
18th Nov 20197:00 amRNSAntibiotic Induced Hearing Loss Assay CE marking
6th Nov 20197:00 amRNSNotice of AGM and Change of Auditors
28th Oct 20197:30 amEQSHardman & Co Research: genedrive plc (GDR): Acceleration of news flow expected
22nd Oct 20193:07 pmRNSHolding(s) in Company
22nd Oct 20193:06 pmRNSHolding(s) in Company
7th Oct 20197:00 amRNSNHS Ethics approval for use of AIHL test in trials
3rd Oct 20197:00 amRNSFinal Results
9th Sep 20197:00 amRNSNotice of Results
18th Jul 20197:30 amEQSHardman & Co Research: genedrive plc (GDR): Hepatitis C market frustrations
18th Jul 20197:00 amRNSDirector/PDMR Shareholding
9th Jul 20197:00 amRNSTrading Update
8th Apr 201910:54 amEQSHardman & Co Research: genedrive plc (GDR): First commercial sales in new focus area: bio-threats
5th Apr 20198:29 amRNSDirector/PDMR Shareholding
28th Mar 20197:00 amRNSHalf-year Report
16th Jan 20191:21 pmRNSHolding(s) in Company
15th Jan 20197:00 amRNSTrading update
31st Dec 201811:30 amRNSResult of AGM
12th Dec 20187:49 amRNSHolding(s) in Company
11th Dec 20187:15 amEQSHardman & Co Research: genedrive plc (GDR): Accelerating into fiscal 2019 with first sales
10th Dec 20184:44 pmRNSHolding(s) in Company
10th Dec 20183:40 pmRNSHolding(s) in Company
10th Dec 201811:04 amRNSHolding(s) in Company
7th Dec 20183:07 pmRNS2018 Annual Report and AGM Notice
7th Dec 20182:59 pmRNSResult of GM
29th Nov 20187:00 amRNSAbbVie to use HCV assay in study
19th Nov 20183:27 pmRNSPosting of Shareholder Circular
16th Nov 20181:42 pmRNSResult of Equity Placing
16th Nov 20187:00 amRNSProposed Placing and Broker Option
16th Nov 20187:00 amRNSUnaudited Preliminary Results
10th Sep 20181:46 pmRNSDirector/PDMR Shareholding
5678910111213

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.